- DVLA Guidelines make it simpler for drivers with insulin treated diabetes
- A no deal Brexit could put lives at risk
- New Ulcer treatment could prevent 3,000 amputations a year
- FreeStyle Libre latest News!!!
- NHS Long-Term Plan
- FreeStyle Libre on the NHS from April 2019 but…
- Pork insulin availability in the UK and Canada assured
- NHS to provide life changing glucose monitors for Type 1 Diabetes patients
- Leading experts slam current diabetes care in UK care homes – a Call to Action needed
- Roche announces urgent recall on certain Accu-Chek Aviva and Performa test strips
- Ramadan 2018 and fasting
- DVLA changes regulations
- Freestyle Libre available on the NHS!
- Medtronic recall specific lots of infusion sets with all models of Medtronic insulin pumps
- All Accu-Chek® Insight insulin pumps – risk of alarm failure
- WHO – long-acting analogues not an essential medicine
- Beef insulin discontinued
- Soft Drinks Warning!
- Driven to Despair
- 2017 – Getting back on track after Christmas
- Childhood Obesity Strategy failing our children
- Diabetes – What schools need to know
- DVLA – Good News!
- The National Diabetes Foot Care Audit (NDFA)
- Diabetes care criticised
- Motorists banned in error after faulty DVLA visual field test
- Too many children and young people with diabetes not getting the care they need
- National NHS Diabetes Prevention Programme
- InDependent Diabetes Trust: Young diabetics ‘get worse care’
- IDDT’s Position Statement – ‘pre-diabetes’
- MBE Is Bolt From The Blue For Charity Chair
- New insulin on the market – Insulin Degludec (Tresiba)
- Diabetes community urges more support for older people
- Warning to people with diabetes about dangerous herbal medicine
- In 1 week, 60 hospital patients with diabetes develop preventable complications – National Audit
- Passport for Diabetes in Care Settings
- Launch of Passport for Diabetes in Care Settings
- Type 2 Diabetes – Management & Medication
- Cost of insulin analogues
- Actos And The Risk Of Bladder Cancer – New Safety Warnings
- Actraphane – are patients really at the centre of care
- Marketing of insulin – a missed opportunity
- IDDT Launch Patient Hospital Passports
- IDDT Launch Public Awareness Campaign
- IDDT’s Position Statement on DTCA
- In Sickness and in Health
- IDDT Triumphs in Australia
Actraphane – are patients really at the centre of care?
19th January, 2011
Diabetes charity questions whether patients really are at the centre of care
In June 2010, when 90,000 people with diabetes were given 6 months notice that the type of insulin they had been successfully using, Mixtard 30, was to be discontinued by the manufacturer, Novo Nordisk, the Insulin Dependent Diabetes Trust [IDDT] wrote to the Secretary of State for Health, Mr Andrew Lansley, asking for his help.
IDDT highlighted the effects of this change of insulin and injection device on the health and wellbeing of 90,000 people, the pressure only six months notice would put on the NHS staff and the present and future increased costs to the NHS incurred by the change and the ongoing monitoring of those affected.
Jenny Hirst, Co-chair of IDDT comments, “We were surprised that Mr Lansley’s response showed so little understanding of the effects this withdrawal would have on patients but also on the NHS. He showed an unwillingness to take any action on behalf of patients, especially the most vulnerable groups – those with visual impairment and manual dexterity problems who, as a result of this withdrawal would lose the injection device that enabled them to self-inject and maintain their independence“.
IDDT investigated the situation further and discovered from the MHRA , the government’s own regulatory agency, that a similar or near identical insulin made by Novo Nordisk, Actraphane, is licensed in the UK and can be prescribed and dispensed under the NHS. The same injection devices are available as for Mixtard 30 and patients could then simply have been changed to Actraphane and continued to use the same injection device.
Jenny Hirst added, “Novo Nordisk may have commercial reasons for withholding this information, but patients have been badly let down by Mr Lansley and his Department. The failure to inform patients, and health professionals, that Actraphane is licensed in the UK has denied patients the informed choice of treatment to which they are entitled. Government policy of ‘patients being at the centre of care’ appears to have been ignored for 90,000 people with diabetes“.
IDDT has informed members of the availability of Actraphane and the availability of the injection device for people with visual impairment and manual dexterity difficulties. However, the Department of Health has failed to provide patients with a fully informed choice of treatment options and failed to put them at the centre of care.
For further information contact: